The Application of Biomarkers in the Care of Patients With Atrial Fibrillation

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07565337

Enrollment

Registered

2026-05-04

Start date

2026-01-01

Completion date

2028-12-31

Last updated

2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation, Biomarker

Keywords

biomarker, atrial fibrillation, AF burden, inflammation, fibrosis, heart failure

Brief summary

From 2020 to 2023, we established a longitudinal AF patient cohort with comprehensive clinical data collection. In our previous work, we utilized the Milliplex platform to screen 52 circulating biomarkers and identified several candidates potentially associated with AF burden. Building on these findings, the present study aims to further validate these biomarkers in a larger subset of patients (n=266) who completed paired pre- and post-intervention sampling. Targeted biomarkers may include NT-proBNP, IL-6, hs-CRP, Adipsin, GDF-15, sST-2, FABP3, and IGF-BP3. Our goal is to identify markers associated with AF burden, assess their predictive performance and subgroup consistency, and further elucidate the underlying pathophysiological mechanisms.

Detailed description

With an aging population and advances in medical care, the prevalence of atrial fibrillation (AF) continues to rise. Although the introduction of novel oral anticoagulants has reduced the risk of stroke, AF can still lead to myocardial ischemia, fibrosis, and ultimately heart failure and valvular dysfunction. Given its often paroxysmal nature, the diagnosis and assessment of AF burden remain challenging and frequently rely on prolonged electrocardiographic monitoring. Identifying accessible and reliable blood-based biomarkers could provide a cost-effective alternative to time-consuming and expensive wearable or implantable monitoring devices, offering significant clinical value.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

-Who have signed up for the Protocol No. 202003090RINA(National Taiwan University Hospital Atrial Fibrillation Integrated Care Pilot Program)

Exclusion criteria

-Subjects without complete pre- and post-treatment testing

Design outcomes

Primary

Measure	Time frame	Description
Novel biomarkers	1YEARS	Whether novel biomarkers are associated with atrial fibrillation burden and could serve as tools to assist clinicians in diagnosing and treating patients, including tracking treatment effectiveness or the timeline for progression to heart failure;

Countries

Taiwan

Outcome results